Efficacy and acceptability of three prolactin-sparing antipsychotics in patient with schizophrenia: a network meta-analysis

References

• Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86–97. doi:10.1016/S0140-6736(15)01121-6.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379:270–280. doi:10.1056/NEJMra1801490.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl). 2013;225:1–19. doi:10.1007/s00213-012-2921-8.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics–a review. Hum Psychopharmacol. 2010;25:281–297. doi:10.1002/hup.1116.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–763. doi:10.1210/edrv.22.6.0451.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21:911–936. doi:10.2165/00023210-200721110-00004.
   PubMed Web of Science ®Google Scholar
• Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry. 2011;45:830–837. doi:10.3109/00048674.2011.589044.
   PubMed Web of Science ®Google Scholar
• Meaney AM, O’Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci. 2002;71:979–992.
   PubMed Web of Science ®Google Scholar
• Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(Suppl):S75–S86.
   Google Scholar
• Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull. 2002;36:143–164.
   PubMedGoogle Scholar
• Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(Suppl 1):53–67.
   PubMed Web of Science ®Google Scholar
• Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57:485–491.
   PubMed Web of Science ®Google Scholar
• Walker SE, Allen SH, Hoffman RW, et al. Review: prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus. 1995;4:3–9. doi:10.1177/096120339500400102.
   PubMed Web of Science ®Google Scholar
• Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 1977;37:951–963.
   PubMed Web of Science ®Google Scholar
• Wong-Anuchit C. Clinical management of antipsychotic-induced hyperprolactinemia. Perspect Psychiatr Care. 2016;52:145–152. doi:10.1111/ppc.12111.
   Web of Science ®Google Scholar
• Boyd A. Bromocriptine and psychosis: a literature review. Psychiatr Q. 1995;66:87–95.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273–288. doi:10.1210/jc.2010-1692.
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Bradley A, Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem. 2010;47:292–300. doi:10.1258/acb.2010.010025.
   PubMed Web of Science ®Google Scholar
• Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol. 2012;26:42–51. doi:10.1177/0269881112442016.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Ahl J, Liu-Seifert H, et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31:577–588. doi:10.1016/j.psyneuen.2005.12.006.
   PubMed Web of Science ®Google Scholar
• Dogan Bulut S, Bulut S, Tuzer V, et al. The effects of prolactin-raising and prolactin-sparing antipsychotics on prolactin levels and bone mineral density in schizophrenic patients. Noro Psikiyatr Ars. 2014;51:205–210. doi:10.4274/npa.y6628.
   Google Scholar
• Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(Suppl 2):S108–S114. doi:10.1016/j.euroneuro.2008.02.004.
   PubMed Web of Science ®Google Scholar
• Miyamoto BE, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015;45:266–272. doi:10.3928/00485713-20150501-09.
   Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–784. doi:10.7326/M14-2385.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962. doi:10.1016/S0140-6736(13)60733-3.
   PubMed Web of Science ®Google Scholar
• Higgins JE. Cochrane handbook for systematic reviews of interventions. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie. 2011;5:S38.
   Google Scholar
• van Valkenhoef G, Tervonen T, Zhao J, et al. Multicriteria benefit-risk assessment using network meta-analysis. J Clin Epidemiol. 2012;65:394–403. doi:10.1016/j.jclinepi.2011.09.005.
   PubMed Web of Science ®Google Scholar
• Valkenhoef GV, Tervonen T, Zwinkels T, et al. ADDIS: a decision support system for evidence-based medicine. Decis Support Syst. 2013;55:459–475.
   Web of Science ®Google Scholar
• Hillege H, Brock BD, Valkenhoef GV, et al. ADDIS: an automated way to do network meta-analysis. Research Report 2012.
   Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel trial 13 study group. Biol Psychiatry. 1997;42:233–246.
   PubMed Web of Science ®Google Scholar
• Cantillon M, Prakash A, Alexander A, et al. Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophr Res. 2017;189:126–133. doi:10.1016/j.schres.2017.01.043.
   Web of Science ®Google Scholar
• Crespo-Facorro B, Perez-Iglesias R, Mata I, et al. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison. J Clin Psychopharmacol. 2013;33:215–220. doi:10.1097/JCP.0b013e3182825c1e.
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28:S20–S28. doi:10.1097/JCP.0b013e318169d4ce.
   PubMed Web of Science ®Google Scholar
• Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76:e1574–e1582. doi:10.4088/JCP.15m09997.
   PubMed Web of Science ®Google Scholar
• Findling RL, Cavus I, Pappadopulos E, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol. 2013;23:531–544. doi:10.1089/cap.2012.0068.
   PubMed Web of Science ®Google Scholar
• Findling RL, McKenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2012;22:327–342. doi:10.1089/cap.2011.0092.
   PubMed Web of Science ®Google Scholar
• Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009;113:49–55. doi:10.1016/j.schres.2009.05.030.
   Web of Science ®Google Scholar
• Keck P Jr., Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140:173–184.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Risinger R, Nasrallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76:1085–1090. doi:10.4088/JCP.14m09741.
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiatry. 1997;54:549–557.
   PubMed Web of Science ®Google Scholar
• Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol. 2007;22:363–370. doi:10.1097/YIC.0b013e32816f7779.
   PubMed Web of Science ®Google Scholar
• Gardner DM, Murphy AL, O’Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686–693. doi:10.1176/appi.ajp.2009.09060802.
   PubMed Web of Science ®Google Scholar
• Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55:29–36. doi:10.1016/j.psym.2013.08.008.
   PubMed Web of Science ®Google Scholar
• Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22:46–55. doi:10.1177/0269881107088435.
   PubMedGoogle Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681–690. doi:10.1001/archpsyc.60.7.681.
   PubMed Web of Science ®Google Scholar
• Kane JM, Meltzer HY, Carson WH Jr., et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213–223.
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189:259–266. doi:10.1007/s00213-006-0564-3.
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123–136.
   PubMed Web of Science ®Google Scholar
• Hanssens L, L’Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the schizophrenia trial of aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;8:95. doi:10.1186/1471-244X-8-95.
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(Suppl 18):47–56.
   PubMed Web of Science ®Google Scholar
• Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study. Eur Psychiatry. 2007;22:433–443. doi:10.1016/j.eurpsy.2007.03.002.
   PubMed Web of Science ®Google Scholar
• Lee BH, Kang SG, Kim TW, et al. Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. Psychiatry Clin Neurosci. 2012;66:69–73. doi:10.1111/j.1440-1819.2011.02296.x.
   Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64:1048–1056.
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763–771.
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6:325–337. doi:10.1017/S1461145703003651.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006;85:254–265. doi:10.1016/j.schres.2006.03.027.
   PubMed Web of Science ®Google Scholar
• Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14:163–173.
   PubMedGoogle Scholar
• Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res. 1999;35(Suppl):S67–S73.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291–2314. doi:10.2165/00003495-200464200-00003.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim SH, Lee NY, et al. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry. 2012;45:57–63. doi:10.1055/s-0031-1291175.
   Web of Science ®Google Scholar
• Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci. 2005;42:51–60.
   Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int J Impot Res. 2005;17:201–203. doi:10.1038/sj.ijir.3901260.
   PubMed Web of Science ®Google Scholar
• Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013:CD006625. doi:10.1002/14651858.CD006625.pub3.
   Web of Science ®Google Scholar
• Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96:265–273.
   PubMed Web of Science ®Google Scholar
• Riedel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005;255:432–437. doi:10.1007/s00406-005-0622-6.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res. 2004;66:143–150. doi:10.1016/j.schres.2003.06.001.
   PubMed Web of Science ®Google Scholar
• Byerly MJ, Lescouflair E, Weber MT, et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther. 2004;30:325–332. doi:10.1080/00926230490465082.
   PubMed Web of Science ®Google Scholar
• Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry. 2010;71:1131–1137. doi:10.4088/JCP.08m04307yel.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31:340–346. doi:10.1016/j.psyneuen.2005.08.010.
   PubMed Web of Science ®Google Scholar
• Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65:696–701.
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘seroquel’) and haloperidol in schizophrenia. Psychol Med. 2000;30:95–105.
   PubMed Web of Science ®Google Scholar
• King DJ, Link CG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998;137:139–146.
   Web of Science ®Google Scholar
• Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159:133–135. doi:10.1176/appi.ajp.159.1.133.
   PubMed Web of Science ®Google Scholar
• Wong J, Seeman MV. Prolactin, menstrual irregularities, quality of life. Schizophr Res. 2007;91:270–271. doi:10.1016/j.schres.2006.11.004.
   Web of Science ®Google Scholar
• Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65:1491–1498.
   PubMed Web of Science ®Google Scholar
• Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21:768–773. doi:10.1177/0269881107078281.
   PubMed Web of Science ®Google Scholar
• Bushe C, Yeomans D, Floyd T, et al. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol. 2008;22:56–62. doi:10.1177/0269881107088436.
   PubMedGoogle Scholar
• Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296–304.
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49(Suppl 1):5S–13S.
   Google Scholar
• Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65:1624–1633.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr Bull. 2004;30:767–779.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li H, Shu L, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Neuropsychiatr Dis Treat. 2011;7:77–85. doi:10.2147/NDT.S16664.
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Rettenbacher MA, et al. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? results from a prospective study. J Clin Psychiatry. 2009;70:293–294.
   Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;110:80–89. doi:10.1016/j.schres.2009.02.017.
   PubMed Web of Science ®Google Scholar
• Addington DE, Labelle A, Kulkarni J, et al. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009;54:46–54. doi:10.1177/070674370905400108.
   PubMed Web of Science ®Google Scholar
• Arato M, O’Connor R, Meltzer HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the ziprasidone Extended Use in schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207–215.
   PubMed Web of Science ®Google Scholar
• Tsuboi T, Bies RR, Suzuki T, et al. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:178–182. doi:10.1016/j.pnpbp.2013.05.010.
   Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33:121–125. doi:10.1097/WNF.0b013e3181d52b85.
   PubMed Web of Science ®Google Scholar
• Wu XL, Wang JH, Hu SH, et al. Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian Arch Psychiatry. 2012;22:7–11.
   Google Scholar
• Suzuki T, Graff-Guerrero A, Uchida H, et al. Dopamine D(2)/(3) occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology (Berl). 2013;228:43–51. doi:10.1007/s00213-013-3012-1.
   Web of Science ®Google Scholar
• Grootens KP, van Veelen NM, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37:352–361. doi:10.1093/schbul/sbp037.
   PubMed Web of Science ®Google Scholar
• Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23:305–314. doi:10.1177/0269881108089593.
   PubMed Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195–1203. doi:10.1093/schbul/sby058.
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(Suppl 2):55–68.
   PubMed Web of Science ®Google Scholar
• Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003;9:344–353.
   PubMedGoogle Scholar
• Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454–465.
   PubMed Web of Science ®Google Scholar
• Kirsch I, Moncrieff J. Clinical trials and the response rate illusion. Contemp Clin Trials. 2007;28:348–351. doi:10.1016/j.cct.2006.10.012.
   PubMed Web of Science ®Google Scholar